凤凰网科技讯 北京时间7月3日，据《商业内幕》报道，特斯拉公司刚刚经历了有史以来最大一次季度 交付量滑坡，但从股价走势上看，外界可能察觉不到这一点。 特斯拉在第二季度交付了大约38.4万辆电动车，较上年同期的44.4万辆下降了13.5%。尽管特斯拉交付 量同比大跌，但好于华尔街的"更糟糕预期"。一些投资者原本预计，特斯拉第二季度交付量将大跌超 20%。受到这一"超出预期"交付量的推动，特斯拉股价周三收盘时上涨了5%。 没那么糟糕 特斯拉的交付量报告基本符合分析师的平均预期，而且好于华尔街最悲观的预测。 在连续两个季度销量下滑后，特斯拉正寻求重新实现增长。但问题是，交付量缺口越大，特斯拉要实现 这一目标所面临的挑战就越艰巨。 今年上半年，特斯拉共交付了大约72.07万辆电动车。要想超过2024年交付的178.9226万辆，特斯拉需要 在接下来的两个季度交付超过100万辆电动车。2024年，特斯拉年度交付量已经遭遇下滑。 特斯拉年交付量可能再次下滑 这虽然有可能实现，但对于特斯拉来说是一项艰巨任务。去年第三季度，特斯拉交付了46.289万辆，第 四季度则交付了大约49.5万辆，两个季度加起来不到100万辆。 "我 ...

增长前景黯淡，大幅下调2025-27年盈利预期 汇丰基于4月和5月实际交付数据以及历史6月季节性规律分析，预计特斯拉Q2交付量将环比持平。这一 预测较当前市场共识低15%，主要原因包括产品组合老化、竞争加剧以及品牌形象担忧等结构性问题。 汇丰警告特斯拉盈利将持续令人失望，Robotaxi规模化面临三重严峻挑战。 据追风交易台，汇丰银行在最新的报告中维持特斯拉"减持"评级，目标价120美元不变，暗示较当前股 价有63%的下行空间。 基于4月和5月实际销量数据以及6月历史季节性因素，汇丰预测第二季度交付量环比持平，较市场预期 低15%，运营收入面临8%的下行风险。 汇丰分析师Michael Tyndall指出，特斯拉销量疲软源于产品老化、竞争加剧和品牌形象担忧，新款 Model Y改款对提振销量的作用有限。 汇丰还大幅下调2025-27年交付和盈利预期，预期RobotaxiAI计算成本上升但短期内难以贡献收入和利 润。汇丰认为，在没有明确推出价格低于2.5万美元的更实惠车型迹象下，中期销量增长将保持温和。 尽管改款Model Y已经推出，但似乎未能有效阻止销量下滑趋势。汇丰预计Q2生产情况将好于Q1，汽 车业务毛 ...

Mersana Therapeutics (MRSN) Q1 2025 Earnings Call May 15, 2025 08:00 AM ET Company Participants Jason Fredette - Senior Vice President of Investor Relations & Corporate CommunicationsMartin Huber - President & CEOBrian DeSchuytner - Senior VP, CFO & COOJonathan Chang - Senior Managing DirectorKarina Rabayeva - VP - Biotech Equity Research Conference Call Participants Tara Bancroft - Director, Senior Analyst, Biotech Equity ResearchCharles Zhu - Managing Director, Senior Biotechnology Research AnalystMichael ...

1. 总收入端低于市场预期： 本季度总收入端193.4亿，虽然明显差于老旧的市场预期，但相比海豚君看到的特斯拉销量发布后大行更新的200亿上下的汽车收入， 算是稍低一点点。 2. 但在最核心的卖车业务上，本季度卖车毛利率要超市场预期： 在市场最关心的纯卖车业务毛利率上（去除碳积分影响后），本季度达到12.5%，虽然环比上季度 下滑1.1个百分点，但由于一季度的销量低点，叠加由于Model Y Juniper发布导致的停产影响，市场对于下滑的卖车毛利率早有预期，市场对于本季度纯卖车毛利 率的一致预期在12.2%，而海豚君看到的部分大行更为悲观，预期已经降低到11%-12%左右，有些甚至都在个位数，所以在纯卖车毛利率上，特斯拉本季度表现是 要超出市场预期的。 3. 卖车单价本季度基本稳住： 从卖车的单价端来看，一季度，特斯拉每卖一辆车的收入（不含碳积分与汽车租赁销售）是4万美元，相比上季度还要3.98万美元还 要环比提升200美元，卖车单价在一季度低谷期基本稳住，所以卖车单价表现海豚君认为还可以。而海豚君认为本季度卖车单价能维稳的原因在于Model Y Juniper 上市的高起售价，对冲了融资促销等激励措施，以 ...

特斯拉(TSLA.O)于北京时间4月22日凌晨美股盘后发布了2025年第一季报，交出了一个看似起来又是很差，但实际上却隐藏着改善信息的业绩。来看核心信息： 1. 总收入端低于市场预期： 本季度总收入端193.4亿，虽然明显差于老旧的市场预期，但相比海豚君看到的特斯拉销量发布后大行更新的200亿上下的汽车收入， 算是稍低一点点。 2. 但在最核心的卖车业务上，本季度卖车毛利率要超市场预期： 在市场最关心的纯卖车业务毛利率上（去除碳积分影响后），本季度达到12.5%，虽然环比上季度 下滑1.1个百分点，但由于一季度的销量低点，叠加由于Model Y Juniper发布导致的停产影响，市场对于下滑的卖车毛利率早有预期，市场对于本季度纯卖车毛利 率的一致预期在12.2%，而海豚君看到的部分大行更为悲观，预期已经降低到11%-12%左右，有些甚至都在个位数，所以在纯卖车毛利率上，特斯拉本季度表现是 要超出市场预期的。 3. 卖车单价本季度基本稳住： 从卖车的单价端来看，一季度，特斯拉每卖一辆车的收入（不含碳积分与汽车租赁销售）是4万美元，相比上季度还要3.98万美元还 要环比提升200美元，卖车单价在一季度低谷期基本稳 ...

About Processa Pharmaceuticals, Inc. Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa's NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its ...

Core Insights - Processa Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing next-generation cancer therapies with enhanced efficacy and safety [1][5] - Dr. David Young, the Founder and President of Research & Development, will present at the World Orphan Drug Congress USA 2025, discussing FDA's Project Optimus principles [2][3] Company Overview - Processa's strategy involves modifying existing FDA-approved oncology therapies to improve their metabolism and distribution while retaining their cancer-killing mechanisms [5] - The company aims to develop more effective therapy options with better tolerability for cancer patients through an efficient regulatory path [5] Presentation Details - Dr. Young's presentation is titled "Applying Principles of FDA's Project Optimus to Oncology and Non-Oncology Rare Diseases" and is scheduled for April 24, 2025 [2][3] - The presentation will focus on optimizing drug dosing to enhance the balance of efficacy and safety for rare oncology and non-oncology diseases [3]

Industry Overview - The Zacks Domestic Auto industry encompasses companies involved in designing, manufacturing, and retailing various types of vehicles, including passenger cars, trucks, and electric vehicles [2] - The industry is highly consumer cyclic and is undergoing significant transformation due to technological advancements and digitization [2] Factors Affecting Industry Prospects - The newly introduced tariff by President Trump is expected to worsen affordability issues, with average new car prices nearing $50,000, potentially leading to higher costs for consumers [3] - Economic uncertainty is projected to impact demand, with the Fed reducing its GDP growth forecast for 2025 from 2.1% to 1.7% and raising core inflation estimates to 2.8% [4] - The introduction of more affordable electric vehicles (EVs), priced at $35,000 or less, is anticipated to attract buyers despite economic challenges [5] Current Industry Ranking and Performance - The Zacks Automotive – Domestic industry currently holds a Zacks Industry Rank of 188, placing it in the bottom 23% of 250 Zacks industries, indicating dim near-term prospects [6][7] - The industry's earnings estimates for 2025 and 2026 have decreased by 42.9% and 15.6%, respectively, over the past year, reflecting a negative earnings outlook [8] Market Performance - Over the past year, the Domestic Auto industry has outperformed the auto sector but lagged behind the Zacks S&P 500 composite, with a decline of 4.2% compared to the sector's 16.4% and S&P 500's 1.9% [11] Valuation Metrics - The industry is currently trading at an EV/EBITDA ratio of 26.02X, significantly higher than the S&P 500's 14.96X and the sector's 14.69X, indicating a premium valuation despite being debt-laden [14] Company Highlights - **Blue Bird Corporation (BLBD)**: Engaged in manufacturing school buses, with a strong order backlog of nearly 4,400 units. The company expects a record full-year adjusted EBITDA margin of 14% for fiscal 2025 [19][20] - **Tesla, Inc. (TSLA)**: Recognized as a technology innovator in the EV space, with plans for Full Self-Driving services and new product launches expected to enhance profitability. The Zacks Consensus Estimate for 2025 sales and EPS implies year-over-year growth of 7.54% and 9.92%, respectively [23][24] - **General Motors Company (GM)**: Holds a 16.5% market share in the U.S. and has achieved significant cost reductions. The Zacks Consensus Estimate for GM's 2025 EPS indicates year-over-year growth of 8.58% [27][28]